Effect of Kinesiotaping on Muscle Activity

September 3, 2021 updated by: Hilal Denizoğlu Külli, Bezmialem Vakif University

The Effect of Kinesiotaping on Bioelectrical Muscle Activity

The aim of the investigator's study is to analyze the effect of kinesiotaping (KT) on the electrical activity of the muscle by using time and frequency domain analysis of the electromyography (EMG) signals.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The kinesiotaping (KT) is a taping technique that is commonly used to improve muscle performance and facilitate or inhibit muscle activity in rehabilitation. A study reported that KT application did not change electrical activity in the early period (immediately after KT, 5th and 10 minutes after KT). However, another study showed that EMG activity increased 24 hours after KT application. A study revealed that the KT produced more EMG activity compare to placebo taping. In conclusion, the effect of KT on electrical muscular activity was arguable in the literature.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
38

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Bezmialem Vakıf University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • To be right-handed-dominant
  • To have normal or corrected vision
  • To have no formal history of any resistance training.

Exclusion Criteria:

  • To have history of neurological or recent musculoskeletal injury

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Kinesiotaping Group
The group in which kinesiotaping is going to be applied to biceps brachii muscle of participants and will assess EMG activities before KT, immediately after KT, after 30 minutes and 24 hours of KT. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.
Other: Kinesiotaping
For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
No Intervention: Control Group
The group in which kinesiotaping is not going to be applied. EMG activities will be assessed first assessment and after 10th minutes, 30th minutes and 24th hours of the first assessment. The EMG analysis will be performed during maximum isometric voluntary contraction of biceps brachii muscle.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The first assessment of electromyographic activity
Time Frame: at inclusion
The electromyographic activity of biceps brachii muscle will be measured during elbow maximum isometric flexion by using electromyography device before KT for KT group or as a first assessment of the control group. The test will be repeated three times.
at inclusion
The second assessment of electromyographic activity
Time Frame: after KT application for KT group or at 10th minutes after the first assessment
The electromyographic activity of biceps brachii muscle will be measured during elbow maximum isometric flexion by using electromyography device immediately after KT application for KT group or at 10th minutes after the first assessment as a second assessment of the control group. The test will be repeated three times.
after KT application for KT group or at 10th minutes after the first assessment
The third assessment of electromyographic activity
Time Frame: 30 minutes after the second assessment
The electromyographic activity of biceps brachii muscle will be measured during elbow maximum isometric flexion by using electromyography device at 30 minutes after the second assessment. The test will be repeated three times.
30 minutes after the second assessment
The last assessment of electromyographic activity
Time Frame: at 24 hours after KT application or the second assessment
The electromyographic activity of biceps brachii muscle will be measured during elbow maximum isometric flexion by using electromyography device at 24 hours after KT application or the second assessment. The test will be repeated three times.
at 24 hours after KT application or the second assessment

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The first assessment of maximum isometric voluntary contraction torque
Time Frame: at inclusion
The produced elbow flexion torque during first EMG assessment will be recorded at 90° elbow flexion using isokinetic dynamometer.
at inclusion
The second assessment of maximum isometric voluntary contraction torque
Time Frame: after KT application for KT group or at 10th minutes after the first assessment
The produced elbow flexion torque during second EMG assessment will be recorded at 90° elbow flexion using isokinetic dynamometer.
after KT application for KT group or at 10th minutes after the first assessment
The third assessment of maximum isometric voluntary contraction torque
Time Frame: 30 minutes after the second assessment
The produced elbow flexion torque during third EMG assessment will be recorded at 90° elbow flexion using isokinetic dynamometer.
30 minutes after the second assessment
The last assessment of maximum isometric voluntary contraction torque
Time Frame: at 24 hours after KT application or the second assessment
The produced elbow flexion torque during the last EMG assessment will be recorded at 90° elbow flexion using isokinetic dynamometer.
at 24 hours after KT application or the second assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bezmialem Vakif University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Istanbul University - Cerrahpasa (IUC)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 12, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 12, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 13, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 8, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 15, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 20, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 5, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 3, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • hdenizkulli4

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings